Key clinical point: Tisagenlecleucel showed positive safety and clinical outcomes in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) who achieved a complete response after bridging therapy.

Major finding: Tisagenlecleucel rapidly expanded in all 7 patients during the first 28 days after infusion and 5 patients remained progression free for longer than 12 months.

Study details: A post hoc exploratory analysis from the JULIET trial of 7 patients with relapsed/refractory DLBCL without measurable disease prior to receiving tisagenlecleucel therapy.

Disclosures: The study was funded by Novartis. The authors reported financial affiliations with Novartis and several other companies.